# **Special Issue**

# Drug Metabolism, Interactions and Toxicity: Advances in Metabolomics Approaches

# Message from the Guest Editors

This Special Issue is devoted to metabolomics in drug toxicity, with a focus on drug metabolism, drug-drug (food) interactions, and drug-endobiotic interactions. The scope of this Special Issue includes, but is not limited to, studies on targeted and untargeted metabolomic analyses, multi-omics integration, and computational modeling to characterize how investigational drug candidates and approved drugs perturb the endobiotic network; drug-endobiotic interactions; the development of endogenous probes for drug-drug (food) interactions; the development of biomarkers for toxicity assessment and prediction; and the identification of the mechanisms and molecular pathways involved in drug toxicity. Other topics with a similar focus will also be considered. The keywords are as follows:

- metabolomics
- drug/xenobiotic metabolism
- drug-drug interactions
- drug-endobiotic interactions
- drug toxicity
- biomarkers
- ADME
- 3D in vitro model

#### **Guest Editors**

Dr. Pengcheng Wang


Translational Medicine, Novartis Biomedical Research, Cambridge, MA 02139, USA

Prof. Dr. Rheem A. Totah

Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195, USA

## Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/249304

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





# Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

### Editor-in-Chief

#### Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

